| AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC (NCT05522894) | Chinese Academy of Medical Sciences | 2022-10-01 |
| A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid Tumors (NCT05499715) | Chinese Academy of Medical Sciences | 2022-09-30 |
| FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage (NCT05279677) | Chinese Academy of Medical Sciences | 2022-08-12 |
| Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer (NCT05484024) | Chinese Academy of Medical Sciences | 2022-08-06 |
| Low-dose Radiotherapy in iNHL (NCT05543070) | Chinese Academy of Medical Sciences | 2022-05-01 |
| Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection (NCT05460403) | Chinese Academy of Medical Sciences | 2022-04-23 |
| Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer (NCT05016869) | Chinese Academy of Medical Sciences | 2022-04-12 |
| Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology (NCT05441098) | Chinese Academy of Medical Sciences | 2022-04-01 |
| Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer (NCT05291910) | Chinese Academy of Medical Sciences | 2022-03-12 |
| A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma (NCT05318339) | Chinese Academy of Medical Sciences | 2022-03-10 |
| Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study (NCT05287308) | Chinese Academy of Medical Sciences | 2022-03-01 |
| Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer (NCT05154396) | Chinese Academy of Medical Sciences | 2022-01-01 |
| Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and Above (NCT05163652) | Chinese Academy of Medical Sciences | 2021-12-18 |
| Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (NCT05164731) | Chinese Academy of Medical Sciences | 2021-12-16 |
| Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC (NCT05343117) | Chinese Academy of Medical Sciences | 2021-12-01 |
| Characteristics and Treatment Trends of Young Breast Cancer in China (NCT05068115) | Chinese Academy of Medical Sciences | 2021-11-01 |
| Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies (NCT04994626) | Chinese Academy of Medical Sciences | 2021-10-01 |
| Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL (NCT05149170) | Chinese Academy of Medical Sciences | 2021-10-01 |
| The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts (NCT05074966) | Chinese Academy of Medical Sciences | 2021-09-06 |
| Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC (NCT05000736) | Chinese Academy of Medical Sciences | 2021-09-01 |
| Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma (NCT05204524) | Chinese Academy of Medical Sciences | 2021-08-27 |
| Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib (NCT05020964) | Chinese Academy of Medical Sciences | 2021-08-20 |
| Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection (NCT04762459) | Chinese Academy of Medical Sciences | 2021-08-01 |
| Real World Study of MPM in China (NCT05042557) | Chinese Academy of Medical Sciences | 2021-06-01 |
| Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China (NCT05194371) | Chinese Academy of Medical Sciences | 2021-06-01 |
| Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT04861467) | Chinese Academy of Medical Sciences | 2021-06-01 |
| TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis (NCT04888546) | Chinese Academy of Medical Sciences | 2021-04-30 |
| Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant Reconstruction (NCT05045287) | Chinese Academy of Medical Sciences | 2021-04-08 |
| Radiotherapy for Extracranial Oligometastatic Breast Cancer (NCT04646564) | Chinese Academy of Medical Sciences | 2021-04-06 |
| Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC (NCT04683198) | Chinese Academy of Medical Sciences | 2021-04-01 |
| A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy (NCT04749394) | Chinese Academy of Medical Sciences | 2021-03-17 |
| Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma (NCT04851132) | Chinese Academy of Medical Sciences | 2021-03-11 |
| Adjuvant Radiotherapy for pT1b Esophageal Cancer After Submucosal Endoscopic Resection (NCT05499195) | Chinese Academy of Medical Sciences | 2021-03-01 |
| The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 (NCT04659239) | Chinese Academy of Medical Sciences | 2021-01-28 |
| Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. (NCT04661696) | Chinese Academy of Medical Sciences | 2020-12-09 |
| The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs (NCT05202275) | Chinese Academy of Medical Sciences | 2020-12-01 |
| The Clinical Effect of Adaptive Posture-balance Cardiac Rehabilitation Exercise on Cardiovascular Diseases (NCT05496153) | Chinese Academy of Medical Sciences | 2020-12-01 |
| Online Noninvasive Assessment of Human Brain Death and Deep Coma by Near-infrared Spectroscopy (NCT04623294) | Chinese Academy of Medical Sciences | 2020-11-10 |
| Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy (NCT04620837) | Chinese Academy of Medical Sciences | 2020-11-01 |
| Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer (NCT04947774) | Chinese Academy of Medical Sciences | 2020-11-01 |
| Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study (NCT04835324) | Chinese Academy of Medical Sciences | 2020-10-01 |
| Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer (NCT04452370) | Chinese Academy of Medical Sciences | 2020-09-23 |
| The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring (NCT04499794) | Chinese Academy of Medical Sciences | 2020-08-01 |
| Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL (NCT04491721) | Chinese Academy of Medical Sciences | 2020-07-01 |
| A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS (NCT04447274) | Chinese Academy of Medical Sciences | 2020-07-01 |
| Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma (NCT04425824) | Chinese Academy of Medical Sciences | 2020-06-15 |
| Comparison of Two Bending Angles for Nasotracheal Intubation With a Malleable Vedio Stylet (NCT04459481) | Chinese Academy of Medical Sciences | 2020-06-04 |
| Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer (NCT05546255) | Chinese Academy of Medical Sciences | 2020-06-01 |
| Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (NCT04390958) | Chinese Academy of Medical Sciences | 2020-05-15 |
| A Real-world Clinical Study of Kapok Initiative (NCT04735991) | Chinese Academy of Medical Sciences | 2020-05-08 |
| Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC (NCT04304638) | Chinese Academy of Medical Sciences | 2020-03-01 |
| Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer (NCT04158505) | Chinese Academy of Medical Sciences | 2020-02-28 |
| Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy (NCT04437160) | Chinese Academy of Medical Sciences | 2020-02-01 |
| Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma (NCT04275986) | Chinese Academy of Medical Sciences | 2020-01-20 |
| HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC (NCT05566457) | Chinese Academy of Medical Sciences | 2020-01-01 |
| Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer (NCT04194684) | Chinese Academy of Medical Sciences | 2019-12-28 |
| Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. (NCT04023916) | Chinese Academy of Medical Sciences | 2019-12-01 |
| Hemodynamic Changes During Dry Cupping Therapy on Low Back Pain (NCT03816787) | Chinese Academy of Medical Sciences | 2019-12-01 |
| Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma (NCT04140318) | Chinese Academy of Medical Sciences | 2019-11-15 |
| PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study (NCT04535739) | Chinese Academy of Medical Sciences | 2019-07-01 |
| Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma (NCT03908372) | Chinese Academy of Medical Sciences | 2019-06-15 |
| PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer (NCT03971214) | Chinese Academy of Medical Sciences | 2019-06-01 |
| Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer (NCT03923179) | Chinese Academy of Medical Sciences | 2019-04-19 |
| Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer (NCT03923166) | Chinese Academy of Medical Sciences | 2019-04-19 |
| Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer (NCT05089643) | Chinese Academy of Medical Sciences | 2019-04-11 |
| Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer (NCT03933319) | Chinese Academy of Medical Sciences | 2019-03-11 |
| Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis (NCT03927898) | Chinese Academy of Medical Sciences | 2019-03-01 |
| The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency (NCT03876886) | Chinese Academy of Medical Sciences | 2019-02-22 |
| A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer (NCT03854617) | Chinese Academy of Medical Sciences | 2019-02-20 |
| Optical Assessment on Brain Death Via a Oxygen Supply Procedure (NCT03864887) | Chinese Academy of Medical Sciences | 2019-02-11 |
| Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer (NCT03815461) | Chinese Academy of Medical Sciences | 2019-02-01 |
| Monitoring Efficacy of Radiotherapy in Lung Cancer and Esophageal Cancer (NCT04014465) | Chinese Academy of Medical Sciences | 2019-02-01 |
| TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC (NCT03916913) | Chinese Academy of Medical Sciences | 2019-01-01 |
| A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer (NCT03933982) | Chinese Academy of Medical Sciences | 2018-12-22 |
| HFSRT With Concurrent TMZ for Large BMs (NCT03778541) | Chinese Academy of Medical Sciences | 2018-12-03 |
| GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma (NCT03731390) | Chinese Academy of Medical Sciences | 2018-11-01 |
| Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer (NCT03735082) | Chinese Academy of Medical Sciences | 2018-11-01 |
| Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients (NCT03731442) | Chinese Academy of Medical Sciences | 2018-11-01 |
| Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma (NCT04072679) | Chinese Academy of Medical Sciences | 2018-10-11 |
| Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma (NCT03639467) | Chinese Academy of Medical Sciences | 2018-09-18 |
| Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR (NCT03947736) | Chinese Academy of Medical Sciences | 2018-09-17 |
| Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC (NCT03636685) | Chinese Academy of Medical Sciences | 2018-08-15 |
| SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer (NCT03603756) | Chinese Academy of Medical Sciences | 2018-07-31 |
| Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal Cancer (NCT03545711) | Chinese Academy of Medical Sciences | 2018-05-26 |
| Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell Lymphoma (NCT04509804) | Chinese Academy of Medical Sciences | 2018-05-10 |
| A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer (NCT04247984) | Chinese Academy of Medical Sciences | 2018-05-01 |
| Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer (NCT04348032) | Chinese Academy of Medical Sciences | 2018-03-22 |
| Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC (NCT03572829) | Chinese Academy of Medical Sciences | 2018-03-01 |
| Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma (NCT03410004) | Chinese Academy of Medical Sciences | 2018-01-25 |
| Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine (NCT03821441) | Chinese Academy of Medical Sciences | 2018-01-04 |
| Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer (NCT02675088) | Chinese Academy of Medical Sciences | 2017-12-01 |
| Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02 (NCT03308552) | Chinese Academy of Medical Sciences | 2017-12-01 |
| The Phase IVd of Inactivated Enterovirus 71 Vaccine (NCT03296410) | Chinese Academy of Medical Sciences | 2017-09-14 |
| Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03 (NCT03328234) | Chinese Academy of Medical Sciences | 2017-09-01 |